Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Active, not recruiting	Not stated	2025-11-19		NCT05382052

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Fundación GECP	15

20 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Complejo Hospitalario de Navarra	Pamplona	Spain	1
Hospital Clínico de Valencia	Valencia	Spain	9
Hospital Clínico San Carlos	Madrid	Spain	29
Hospital Clínico Universitario de Valladolid	Valladolid	Spain	13
Hospital De Basurto	Bilbao	Spain	8
Hospital General Universitario de Alicante	Alicante	Spain	11
Hospital Germans Trias i Pujol	Badalona	Spain	15
Hospital Universitari Quiron Dexeus	Barcelona	Spain	5
Hospital Universitari Son Llatzer	Palma de Mallorca	Spain	6
Hospital Universitari Vall d' Hebron	Barcelona	Spain	12
Hospital Universitario De A Coruna	A Coruña	Spain	2
Hospital Universitario de Jaén	Jaén	Spain	5
Hospital Universitario Fundación Jiménez Díaz	Madrid	Spain	24
Hospital Universitario La Fe	Valencia	Spain	10
Hospital Universitario La Paz	Madrid	Spain	46
Hospital Universitario Lucus Augusti	Lugo	Spain	18
Hospital Universitario Puerta de Hierro	Majadahonda	Spain	30
Hospital Universitario Regional de Málaga	Málaga	Spain	8
Hospital Universitario Reina Sofia	Córdoba	Spain	6
ICO Girona, Hospital Josep Trueta	Girona	Spain	6

Clinical trials